Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Latest Information Update: 07 May 2024
At a glance
- Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 01 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 01 May 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 04 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.